TENT COOPERATION TREATY **PCT**



INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

	(FC1 Article 36 and Rule 70)	
Applicant's or agent's file reference 2002P20377WO FO	R FURTHER ACTION	See Form PCT/IPEA/416
7-1		——————————————————————————————————————
DOT/DECOM (SALLE)	mational filing date (day/month/year)	Priority date (day/month/year)
	December 2003 (15.12,2003)	19 December 2002 (19.12.2002)
International Patent Classification (IPC) or national C12Q 1/68	l classification and IPC	
Applicant		
	ENS AKTIENGESELLSCHAF	
		T
 This report is the international preliminary Authority under Article 35 and transmitted 	examination report established by this	Internal in the second
Authority under Article 35 and transmitted	to the applicant according to Article 3	6.
2. This REPORT consists of a total of		
 This REPORT consists of a total of	sheets, including this cover s	heet.
(sent to the applicant and a	XES, comprising:	
a (sem to the applicant and to the	International Bureau) a total of	sheets, as follows:
sheets of the description,	claims and/or drawings which have be	een amended and are the basis of this report
and/or sheets containing Administrative Instruction	rectifications authorized by this Authorized	en amended and are the basis of this report rity (see Rule 70.16 and Section 607 of the
beyond the disclosure in	the international application as filed	considers contain an amendment that goes as indicated in item 4 of Box No. I and the
Supplemental Box.	Transmin ab Inou, e	is indicated in item 4 of Box No. I and the
b (sent to the International But	reau only) a total of (indicate type	be and number of electronic carrier(s))
readable form only, as indicated	in the Supplemental Box Relating to	g and/or tables related thereto, in computer Sequence Listing (see Section 802 of the
		the beams (see section 802 of the
 This report contains indications relating to the 	he following items:	
Box No. I Basis of the report		
Box No. II Priority		
Box No. III Non-establishment of	opinion with regard to novelty, inventi	
Lack of unity of invent	tion	ve step and industrial applicability
		y, inventive step or industrial applicability;
Box No. VI Certain documents cite	d	
Box No. VII Certain defects in the in	nternational application	
	the international application	
ate of submission of the demand	Date of completion of	
06 July 2004 (06.07.2004)	Date of completion of	·
	26 Au	gust 2005 (26.08.2005)
ame and mailing address of the IPEA/EP	Authorized officer	
		j
acsimile No.	Telephone No.	i
	l reichuous No.	

Translation



Internati pplication No. PCT/DE2003/004136

Box No. I	Basis of the report	PCT/DE2003/004136
otherwise	rd to the language, this report is based on the international application in the indicated under this item.	language in which it was filed, unless
L Th	s report is based on translations from the original language into the follow ich is language of a translation furnished for the purpose of:	ring language
	international search (under Rules 12.3 and 23.1(b))	
	publication of the international application (under Rule 12.4)	
	international preliminary examination (under Rules 55.2 and/or 55.3)	
	(1.2 1.2. 00.2 million 33.5)	
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	ed to the elements of the international application, this report is based on the receiving Office in response to an invitation under Article 14 are refer to annexed to this report):	n (replacement sheets which have been red to in this report as "originally filed"
The	nternational application as originally filed/furnished	
	escription:	
page page	1-16	, as originally filed/furnishe
page	received by this Authority on	
	aims:	
pages pages	1-15	, as originally filed/furnishe
pages	* as amended (to	gether with any statement) under Article
pages	* Teceived by this Authority on	
<u> </u>	received by this Authority on	
	awings:	
pages	1/6-6/6	, as originally filed/furnishe
pages pages	received by this Authority on	, a originally mediumisne
	received by this Authority on	
a sequ	ence listing and/or any related table(s) — see Supplemental Box Relating to Se	equence Listing
		-danies Distill
The ar	nendments have resulted in the cancellation of:	
	the description, pages	
	he claims, Nos	
	he drawings, sheets/figs	
i ii	he sequence listing (specify):	
٠ ا	ny table(s) related to sequence listing (specify):	
(Icuie /	port has been established as if (some of) the amendments annexed to this resince they have been considered to go beyond the disclosure as filed, as 0.2(c)).	eport and listed below had not been indicated in the Supplemental Box
t	ne description, pages	
— <del> </del>	ic claims, Nos.	
₩"	e drawings, sheets/figs	
L ti	e sequence listing (specify):	
aı	y table(s) related to sequence listing (specify):	
item 4 appli	es, some or all of those sheets may be marked "superseded."	
n PCT/IPEA/	409 (Box No. I) (January 2004)	

V.	Reasoned statement under A will 2000
	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
	Booth statement

Statement			· · · · · · · · · · · · · · · · · · ·
Novelty (N)	Claims	4, 7-10, 12, 15	YES
	Claims	1-3,5-6,11,13-14	NO
Inventive step (IS)	Claims		YES
	Claims	4,7~10,12,15	 NO
Industrial applicability (IA)	Claims	1-15	— YES
	Claims		NO

## Citations and explanations

- This report makes reference to the following 5.1 documents:
  - D1: WO 00/62036 A (NERENBERG MICHAEL I; EDMAN CARL F (US); WALKER GEORGE T (US); NANO) 19 October 2000 (2000-10-19)
  - D2: WO 00/60919 A (FENG LANA L; LANDIS GEOFREY C (US); NERENBERG MICHAEL I (US); EDM) 19 October 2000 (2000-10-19)
  - US 6258606 (KOVACS GREGORY T A) D3:
  - US 5736257 (CONRAD DAVID W; CHARLES PAUL T) D4:
  - WO 02/20833 (ZELTZ P, SCHEIDER S (DE)) D5:
  - WO 00/58522 (GILES PATRICK et al. (US) D6:
  - FUCHS A ET AL: 'A SILICON LAB-ON-CHIP FOR D7: INTEGRATED SAMPLE PREPARATION BY PCR AND DNA ANALYSIS BY HYBRIDIZATION' ANNUAL INTERNATIONAL IEEE-EMBS SPECIAL TOPIC CONFERENCE ON MICROTECHNOLGIES IN MEDICINE AND BIOLOGY. PROCEEDINGS, 2 May 2002 (2002-05-02), pages 227-231, XP001180969.

## NOVELTY:

5.2 Claim 1:

> D1 discloses a method for PCR amplification and detection of nucleotide sequences that comprises the

steps (a) to (d) recited in claim 1 (D1, abstract; page 13, line 20 to page 26, line 15; claims 1-47, in particular claims 6, 15, 22, 34; figures 1, 2, 12-15, 22 and 23). Therefore, claim 1 lacks novelty in light of D1. The same applies to D2, a document that has same international filing date as D1 but does not belong to the same patent family (see D2, claims 1-32). Furthermore, D3 also discloses a method that relates to PCR amplification and detection of nucleic acids and discloses steps (a) to (d) (see D3, figures 4(c) and 7; column 3, line 5 to column 4, line 54; claims 1-24; column 8, lines 8-38), and therefore claim 1 lacks novelty also in light of this document. Finally, D6 and D7 likewise disclose this type of method (D6, claims 1-9, figure 2; D7, abstract, figures 1-4) and are prejudicial to the novelty of claim 1.

#### 5.3 Claims 2-3:

Claim 2 lacks novelty, because D1 discloses a method that involves a hydrophilic layer with coupling groups for the covalent bonding of probe molecules (D1, page 56, lines 22-26, figure 16). Furthermore, D6 and D7 disclose this type of reaction layer (D6, page 8, lines 5-14; D7, figure 4). The same applies to claim 3, since the streptavidin layer (see above) disclosed in D1 is a "hydrogel". Therefore, claims 2 and 3 lack novelty in light of D1 or D6 and D7, respectively.

#### 5.4 Claims 5-6:

Claim 5 lacks novelty in light of D3, since this document discloses methods that have an electronically addressable microchip, an insulating layer and a reaction layer with the corresponding

orientation (D3, figure 7). Claim 6 likewise lacks novelty, since D3 discloses silicon substrates (D3, figure 7).

## 5.5 Claims 11 and 13-14

D1 discloses a device comprising a biochip with a hydrophilic reaction layer, and an array of analysis positions (D1, see above). Therefore, claim 11 lacks novelty in light of D1. The same applies to D2 (D2, claims 1-32), D4 (see figures 1-4, claims 1-7, columns 4-6), D6 (claims 1-9, page 8, lines 5-14) and D7 (figures 1-4, abstract). The above-mentioned documents are also prejudicial to the novelty of claim 13, because the devices disclosed in D1-D2, D4, D6 and D7 all comprise carriers for microspots. Claim 14 lacks novelty over D4 (figures 1-5, column 6, lines 12-18), because D4 discloses semiconductor material with an insulating layer (D4, figures 4(a) to 4(c)).

## INVENTIVE STEP:

## 5.6 Claim 4:

D1 is regarded as the closest prior art, since it serves the same general purpose as claim 4. The difference between D1 and claim 4 is that in claim 4, the nucleic acid probe is immobilized on the surface using an acrylamide gel, whereas the method disclosed in D1 uses immobilized streptavidin and biotinylated nucleic acids. The technical effect achieved thereby consists in providing an alternative immobilization possibility for the corresponding probes. Accordingly, the problem to be solved by claim 4 is that of providing a method for PCR amplification and detection of nucleic acids that is based on arrays and provides an alternative

immobilization of nucleic acids on the surface of the array or chip. The problem is solved by the method that is recited in claim 4 and based on an acrylamide gel.

macromolecules or nucleic acids on chip surfaces using acrylamide-based photoactivatable polymer networks (D4, claims 1-7). Since D4 mentions substrates with "patterns" of biomolecules, D4 directly suggests an application for this method based on said technique for immobilization on arrays (the term "array" corresponds to the term "pattern" used in D4; see D4, column 4, line 7 to column 6, line 3, claims 1-7). Therefore, the subject matter of claim 4 is rendered obvious by a combination of D1 and D4.

### 5.8 Claims 7-10:

Claims 7-10 are regarded as obvious in light of a combination of D1 (see above) and D5, since D5 discloses a nested PCR and teaches that this type of reaction can be carried out with immobilized oligonucleotides (D5, figures 1-3, claims 1-15).

## 5.9 Claims 12 and 15:

Claim 12 is obvious in light of a combination of D1 (see above) and D3, since D3 discloses a device that comprises a housing with through-flow (see D3, figure 6(b)). Claim 15 does not involve an inventive step, since the use of thin-layer technology in the field of semiconductor electrodes is a matter of standard practice for a person skilled in the art.